Viking's Obesity Treatments Advance as New Data, Trials Loom, Oppenheimer Says

MT Newswires Live07-31

Viking Therapeutics' (VKTX) obesity drug programs continue to move forward, with new study results expected this quarter, a Phase 3 trial for its oral drug planned for later this year, and another candidate beginning clinical testing, Oppenheimer said Wednesday in a report.

Viking is focusing its lead drug, VK2735, on helping patients keep weight off over time, not just on hitting the highest possible weight-loss number, and the company is building its approach around long-term use and patient choice, Oppenheimer said.

Viking is developing both injectable and oral versions of VK2735, which may give patients more flexibility, the report said. Oppenheimer highlighted VK2809 as a potential treatment for nonalcoholic steatohepatitis, a liver disease, that may attract partnership interest.

Oppenheimer rates Viking stock as outperform with a $100 price target.

Price: 32.13, Change: -1.30, Percent Change: -3.89

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment